“before the end of the year, we should have our pivotal study, so late stage study for rare genetic disease, for kids that have rare genetic disease of the liver”
→ Read the source episode
Completion and public announcement of pivotal Phase 2/3 study results for rare genetic liver disease in pediatric patients by December 31, 2026
Host predicts massive supply chain pain will occur within three weeks.
Batwan predicts Pika will optimize H3 Max to run on consumer hardware in the coming weeks.
Rayam Krishnan predicts that the most valuable evaluation business model will be one focused on independent evaluation rather than supporting model development.
Peter Yang predicts that future founders will prefer to keep companies small rather than scale to large sizes.
Ruby predicts emergence of certification aggregators for microplastics, seed oils, and other avoidance categories.
Peter Yang predicts that agents will enable much faster product development and iteration cycles.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.